Regenxbio RGNX reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Regenxbio beat estimated earnings by 41.61%, reporting an EPS of $6.67 versus an estimate of $4.71.
Revenue was up $377.21 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.29 which was followed by a 3.14% increase in the share price the next day.
Here's a look at Regenxbio's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -1.08 | -1.12 | -1.28 | -0.43 |
| EPS Actual | -1.37 | -1.36 | -1.20 | -1.24 |
| Revenue Estimate | 41.46M | 29.02M | 23.23M | 61.50M |
| Revenue Actual | 30.77M | 22.04M | 18.88M | 21.45M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
